Crucell N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 11 aug 2010 - 12:10

Statutaire naam Crucell N.V.

Titel Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac®-based AIDS Vaccine

Bericht Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announces its intention to participate in an international Phase I clinical trial in the United States and Africa of a combination of two AdVac®-based AIDS vaccine candidates, Ad26.ENVA.01 and Ad35-ENV, in healthy adults who are not infected with HIV. The clinical trial, which will be led by the International AIDS Vaccine Initiative (IAVI), represents a collaboration between IAVI, Crucell, the Ragon Institute, and Beth Israel Deaconess Medical Center (BIDMC), a major teaching hospital of Harvard Medical School.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201008110000000006_2010 - 0811 Crucell and Harvard BIDMC Join Forces with IAVI to Advance Advac®-based AIDS Vaccine.pdf (opens in a new window)

Datum laatste update: 13 maart 2026